Company: INDP
Filing Date: 2025-09-02
Form Type: S-1
Source: 0001493152-25-012531
Chunk: 4

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-09-02
Form: S-1
Chunk 4
---
 warrants or (ii) the offering is a discounted offering where the pricing and discount (including attributing a value of $0.125
per whole share underlying the common warrants) meet the pricing requirements under the Nasdaq Stock Market LLC’s rules. The Series
A common warrants and Series B common warrants will expire on the 5 anniversary and 18-month anniversary,
respectively, of the Warrant Stockholder Approval Date, provided that if the Pricing Conditions are met, the Series A common warrants
and Series B common warrants will expire on the five-year anniversary and 18-month anniversary, respectively, of the
date of issuance. Because we will issue two common warrants for each share and for each pre-funded warrant sold in this
offering, the number of common warrants sold in this offering will not change as a result of a change in the mix of shares of common
stock and pre-funded warrants sold.

We are also registering the shares of common stock issuable from time to time upon the exercise of the pre-funded warrants, common warrants and placement agent warrants offered hereby.

Our shares of common
stock are listed on The Nasdaq Capital Market under the symbol “INDP”. On August 29, 2025, the closing price of our
shares of common stock was $6.50 per share. There is no established public trading market for the common warrants and pre-funded
warrants and we do not expect a market to develop. Without an active trading market, the liquidity of those warrants will be limited.
In addition, we do not intend to list the common warrants or pre-funded warrants on The Nasdaq Capital Market, any other national securities
exchange or any other trading system.

The assumed combined public offering price used throughout this prospectus has been included for illustration purposes only, and may not be indicative of the final offering price. The actual combined public offering price per share and any pre-funded warrants will be negotiated between us and the purchasers, in consultation with the Placement Agent based on the trading of our common stock prior to this offering, among other factors, and will be determined at the time of pricing, and may be at a discount to the then current market price. The recent market price used throughout this prospectus may not be indicative of the final offering price. The final combined public offering price will be a fixed price determined through negotiation between us and investors based upon a number of factors, including our history and our prospects, the state of the biotechnology industry in which we operate, our recent operating results, including results of our